First-pass disposition of (-)-6-aminocarbovir in rats. I. Prodrug activation may be limited by access to enzyme.
نویسندگان
چکیده
Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2', 3'-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean +/- S.D.) in the cytosolic fractions obtained from homogenates of the intestine, liver, and intestinal contents were 0.4 +/- 0.1 (n = 3), 12.2 +/- 1.1 (n = 3), and 15.5 (n = 1) min, respectively. An in situ vascularly perfused intestine-liver (IPIL) study was then carried out (n = 6) to determine the relative contribution of each presystemic organ to the overall first-pass extraction of 6AC. The 6AC extraction ratios in the intestine and liver in the IPIL were found to be 0.08 +/- 0.02 and 0.11 +/- 0.03, respectively. The intestinal extraction ratio was in dramatic contrast to the in vitro results. It was postulated that vascularly delivered 6AC had limited access to the metabolic site in the intestine. A theoretical analysis suggested that the extent of intestinal wall extraction of 6AC would be underestimated by the IPIL and should be determined after oral dosing. To compare intestinal extraction ratio in the IPIL with that after an oral administration, in situ intestinal lumen perfusions (n = 4) and intraportal infusions (n = 3) of 6AC were conducted in two groups of rats. The lumenally administered 6AC was extracted to a much greater extent by the intestine as compared with the IPIL, which presents 6AC to the intestine by the vascular route. The extraction ratio was found to be 0.54 +/- 0.06, which was significantly larger than that obtained in the IPIL.
منابع مشابه
First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism.
A CBV [(-)-carbovir, (-)-carbocyclic 2',3'-didehydro-2', 3'-dideoxyguanosine] prodrug, 6AC [(-)-6-aminocarbovir, (-)-carbocyclic 2',3'-didehydro-2', 3'-dideoxy-6-deoxy-6-aminoguanosine], was previously evaluated in rats, and it exhibited superiority to the parent drug in increasing systemic and central nervous system exposure to CBV. The gut wall was determined to be the dominant site of the fi...
متن کاملFirst-pass Disposition of (2)-6-aminocarbovir in Rats. I. Prodrug Activation May Be Limited by Access to Enzyme
Several in vitro and in situ approaches were used to determine the dominant presystemic activation site for (2)-6-aminocarbovir, (2)-carbocyclic 2*,3*-didehydro-2*,3*-dideoxy-6-deoxy-6-aminoguanosine (6AC) conversion in rats. The in vitro disappearance half-lives (mean 6 S.D.) in the cytosolic fractions obtained from homogenates of the intestine, liver, and intestinal contents were 0.4 6 0.1 (n...
متن کاملPharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity.
The peptidyl prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-Amino)propionyl]a-minobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid, also known as LY544344, was discovered to improve the oral bioavailability of the parent drug (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a potent group II metabotropic glutamate receptor agonist. This prodrug has been shown to deliver high plasma concentrations...
متن کاملHydrazone, Amide, Carbamate, Macromolecular and Other Prodrugs of Doxorubicin
The term prodrug was first used by Albert [1]. Prodrug can be defined as an agent that is transformed after administration, either by metabolism or by spontaneous chemical breakdown, to form a pharmacologically active drug. The prodrug itself is inactive or less active and is converted to active agent in vivo. Targeted prodrug approach is one of the new trends in the treatment of cancer. A lot ...
متن کاملPredictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
Antibody-directed enzyme prodrug therapy (ADEPT) using anti-TAG-72 antibody and geldanamycin (GA) prodrug were validated in vitro. To understand the complexity and to explore optimal therapeutic regimens for ADEPT in vivo, a physiologically based pharmacokinetic model (PBPK) is applied to analyze each anatomical component/organ. The baseline model predicts that active drug tumor/plasma exposure...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Drug metabolism and disposition: the biological fate of chemicals
دوره 27 1 شماره
صفحات -
تاریخ انتشار 1999